# A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

> **NCT00219115** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 493 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00219115
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219115, "A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00219115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*